## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Stamos Capital Partners L.P. Purchases 13,922 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251210T123159 | Somewhat-Bullish | Relevance: 100%
- Stamos Capital Partners L.P. increased its stake in Medtronic PLC (NYSE:MDT) by 29.7% during the second quarter, acquiring an additional 13,922 shares. After this purchase, the firm now owns 60,805 shares of Medtronic, valued at $5.3 million, making it their 28th largest position. Medtronic recently announced a quarterly dividend of $0.71 per share, payable on January 16th, and has received a consensus "Moderate Buy" rating from analysts with an average target price of $110.44.

**2. Ardsley Advisory Partners LP Buys Shares of 70,000 Medtronic PLC $MDT**
- Source: MarketBeat | 20251210T090847 | Somewhat-Bullish | Relevance: 99%
- Ardsley Advisory Partners LP has acquired 70,000 shares of Medtronic PLC (NYSE:MDT) during the second quarter, a new position valued at approximately $6.10 million. This acquisition is part of a broader trend where institutional investors are adjusting their holdings in Medtronic. The medical technology company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**3. Medtronic: This Dividend Aristocrat Is Just Getting Started (NYSE:MDT)**
- Source: Seeking Alpha | 20251209T154326 | Bullish | Relevance: 99%
-  Medtronic is showing renewed momentum with strong growth in cardiac franchises and a raised full-year revenue outlook, particularly benefiting from a surge in U.S. pulsed-field ablation sales. Management's shift to a growth mindset, scaling manufacturing and R&D, positions the company to capture underpenetrated markets while maintaining a sound financial standing. The author maintains a Buy rating on MDT, anticipating 10-11% annual total returns supported by EPS growth and an appealing dividend yield.

**4. Medtronic reports first commercial use of Liberant thrombectomy system**
- Source: MassDevice | 20251210T180055 | Bullish | Relevance: 98%
-  Medtronic announced the first commercial use of its Liberant thrombectomy system, designed for the removal of fresh, soft emboli or thrombi from peripheral arterial and venous systems. The system features an intelligent algorithm that adapts pulse rate for aspiration and advancements in catheter technology, aiming for precise clot removal and reduced blood loss. Medtronic plans further investments in thrombectomy, starting with the Liberant's compatibility with Excipio devices for complex cases.

**5. Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances**
- Source: Zenopa | 20251208T220859 | Bullish | Relevance: 98%
- Orchestra BioMed and Medtronic announced significant advancements in their Atrioventricular Interval Modulation (AVIM) Therapy for uncontrolled hypertension at the 2025 Innovation in Cardiology Intervention (ICI) meeting. This cutting-edge bioelectronic treatment, which can be delivered via a pacemaker firmware upgrade, has received FDA Breakthrough Device Designation and shows promise for millions of patients by offering immediate and sustained blood pressure reductions. The collaboration highlights the potential for transforming hypertension treatment and bringing significant improvements to patient care.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.5x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.2B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.5 |
| Current P/E | 17.8 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.29% (CS: 25) | Weak |
| RSI_14 | 55.1 | Neutral |
| MACD Histogram | -0.43 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $100.77
- **Stop Loss:** $97.09 (3.7% risk)
- **Target:** $104.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 135
- **Position Value:** $13,603.95
- **Portfolio %:** 13.60%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*